Detalles de la búsqueda
1.
Isatuximab-pomalidomide-dexamethasone versus pomalidomide-dexamethasone in patients with relapsed and refractory multiple myeloma: final overall survival analysis.
Haematologica
; 2024 Feb 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-38299578
2.
2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. Hyde.
Haematologica
; 106(11): 2799-2812, 2021 Nov 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34261295
3.
Richter transformation driven by Epstein-Barr virus reactivation during therapy-related immunosuppression in chronic lymphocytic leukaemia.
J Pathol
; 245(1): 61-73, 2018 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-29464716
4.
A novel nano-immunoassay method for quantification of proteins from CD138-purified myeloma cells: biological and clinical utility.
Haematologica
; 103(5): 880-889, 2018 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-29545347
5.
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma.
Lancet Oncol
; 17(8): e328-e346, 2016 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-27511158
6.
Outcomes with two different schedules of bortezomib, melphalan, and prednisone (VMP) for previously untreated multiple myeloma: matched pair analysis using long-term follow-up data from the phase 3 VISTA and PETHEMA/GEM05 trials.
Ann Hematol
; 95(12): 2033-2041, 2016 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-27738789
7.
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.
Lancet Oncol
; 14(11): 1055-1066, 2013 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-24007748
8.
Mutational screening of newly diagnosed multiple myeloma patients by deep targeted sequencing.
Haematologica
; 103(11): e544-e548, 2018 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-29954938
9.
AG5 is a potent non-steroidal anti-inflammatory and immune regulator that preserves innate immunity.
Biomed Pharmacother
; 169: 115882, 2023 Dec 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-37984300
10.
Evaluation of prognostic factors among patients with chronic graft-versus-host disease.
Haematologica
; 97(8): 1187-95, 2012 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-22371184
11.
Health-related quality of life with idecabtagene vicleucel in relapsed and refractory multiple myeloma.
Blood Adv
; 6(4): 1309-1318, 2022 02 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-34933328
12.
Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group.
Lancet Haematol
; 9(2): e143-e161, 2022 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-35114152
13.
International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials.
Leukemia
; 35(1): 18-30, 2021 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32778736
14.
Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage.
Blood Cancer J
; 11(12): 192, 2021 12 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-34857730
15.
Lenalidomide: a new therapy for multiple myeloma.
Cancer Treat Rev
; 34(3): 283-91, 2008 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-18230411
16.
Highlights of the 11th International Workshop on Waldenstrom's Macroglobulinemia: What we learned, and how it will impact scientific discovery and patient care.
Semin Hematol
; 60(2): 59-64, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-37202255
17.
Recommendations for acquisition, interpretation and reporting of whole body low dose CT in patients with multiple myeloma and other plasma cell disorders: a report of the IMWG Bone Working Group.
Blood Cancer J
; 8(10): 95, 2018 10 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-30287814
18.
Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma - an IMWG Research Project.
Blood Cancer J
; 8(12): 123, 2018 11 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-30470751
19.
Bortezomib, a novel proteasome inhibitor, in the treatment of hematologic malignancies.
Cancer Treat Rev
; 31(8): 591-602, 2005 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-16298074
20.
Genetic and pharmacologic evidence that mTOR targeting outweighs mTORC1 inhibition as an antimyeloma strategy.
Mol Cancer Ther
; 13(2): 504-16, 2014 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-24431075